Compare Roundhill Innov-100 0DTE Covered Call Strat ETF (QDTE) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Roundhill Innov-100 0DTE Covered Call Strat ETF vs Summit Therapeutics Inc — how do they compare? Roundhill Innov-100 0DTE Covered Call Strat ETF trades at $29.61, while Summit Therapeutics Inc trades at $14.68 (market cap $11.34B). The key difference: Roundhill Innov-100 0DTE Covered Call Strat ETF is trading nearer its 52-week high, Summit Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| QDTE | SMMT | |
|---|---|---|
Sector | Income / Options Overlay | Health |
52-Week High | $36.60 | $29.32 |
52-Week Low | $26.85 | $13.05 |
Market Cap | — | $11.34B |
Enterprise Value | — | $10.76B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
QDTE trades at $29.22, up 0.31% on the day, with technical indicators signaling a bearish trend. The ETF employs a weekly covered call strategy on the Innovation-100 index, generating high distribution yields. Recent news highlights scrutiny over its fee structure and yield sustainability amid declining volatility. Key financial ratios are unavailable in the provided data, limiting fundamental assessment.
The outlook is cautious due to bearish technicals and yield compression risks. Opportunities exist for income-focused investors seeking weekly distributions, but risks include fee drag and volatility dependence. Investor sentiment is mixed, with media questioning yield math while acknowledging competitive returns in certain periods.
Summit Therapeutics (SMMT) trades at $13.50, down 2.24% on the day, reflecting a bearish technical trend amid negative profitability. The company reported a net loss of $1.08 billion for 2025, with deeply negative ROE and ROA, though a recent asset sale and positive clinical trial data for its oncology candidate provide some operational catalysts. Cash flow remains volatile, with net cash flow turning negative in 2026 projections.
The investment case is binary, hinging on the success of ivonescimab. While analyst consensus is bullish with a $15.57 price target, high volatility and ongoing fiduciary investigations pose significant risks. The stock offers high-reward potential for risk-tolerant investors betting on clinical success, but fundamental weaknesses and cash burn necessitate caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Roundhill Innov-100 0DTE Covered Call Strat ETF
QDTE is an actively managed ETF that seeks to generate income through a covered call strategy on the NASDAQ 100. It primarily holds a portfolio of U.S. government securities and sells 0-DTE (zero days to expiration) index call options on the NASDAQ 100. This highly tactical strategy aims to maximize option premium capture by exploiting the rapid time decay of options expiring on the same day, which provides enhanced income but also exposes the fund to significant volatility and risks associated with daily options settlement.
Read more on QDTE →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
